Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-05-03
2005-05-03
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S172100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220
Reexamination Certificate
active
06887473
ABSTRACT:
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin αvβ3antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3antagonists.
REFERENCES:
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5112946 (1992-05-01), Maione
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202352 (1993-04-01), Okada et al.
patent: 5575815 (1996-11-01), Slepian et al.
patent: 5578704 (1996-11-01), Kim
patent: 5652109 (1997-07-01), Kim
patent: 5652110 (1997-07-01), Kim
patent: 5677181 (1997-10-01), Parish
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5849692 (1998-12-01), Jonczyk et al.
patent: 5866540 (1999-02-01), Jonczyk et al.
patent: 5874081 (1999-02-01), Parish
patent: 5968902 (1999-10-01), Scarborough et al.
patent: 5981478 (1999-11-01), Ruoslahti et al.
patent: 0 576 898 (1993-06-01), None
patent: 0 578 083 (1993-06-01), None
patent: 0 770 622 (1997-05-01), None
patent: 8905155 (1989-06-01), None
patent: 8906356 (1989-07-01), None
patent: 8906536 (1989-07-01), None
patent: 9320229 (1993-10-01), None
patent: WO 9410331 (1994-05-01), None
patent: 9514714 (1995-06-01), None
patent: 9528426 (1995-10-01), None
patent: 9714716 (1997-04-01), None
Pignatelli et al. Hum. Pathol 23: 1159-1166 (1992).*
Gutheil, et al., “Targeted Antiangiogenic Therapy for Cancer Using vitaxin: A Humanized Monoclonal Antibody to the Integrin αvβ3”,Clin. Cancer Research 6:3056-3061 (2000).
Christofanilli, et al., “Angiogenesis Modulation In Cancer Research: Novel Clinical Approaches”,Nature Reviews 1:415-426 (2002).
Pierschbacher, et al., Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion, 1987,J. Biol. Chem.,262:17294-17296.
Folkman, et al., Angiogenesis, 1992,J. Biol. Chem.;267:10931-10934.
Teicher, et al., Potentiation of cytotoxic cancer therapies by TNP-470 alone and with oher anti-angiogenic agents, 1994,Intl. J. Cancer,57:920-925.
Saiki, et al., Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly (RGD), 1990,Jpn. J. Cancer Res.,81:668-675.
Hammes, et al., Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, 1996,Nature Med.,2(5):529-533.
Brooks, et al., Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, 1994,Cell,79:1157-1164.
Clark, et al, Transient functional expression of αvβ3 on vascular cells during wound repair, 1996,Am. J Pathol.,148:1407-1421.
Bauer, et al., In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins and integrins, 1992,J. Cell. Physiol.,153:437-449.
Ingber, Extracellular matrix as a solid state regulator of angiogenesis: identification of new targets for anti-cancer therapy, 1992,Seminars in Cancer Biology,3:57-63.
Hardan et al., Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptide Arg-Gly-Asp mimetics, 1993,Intl. J. Cancer,55:1023-1028.
Hynes, Integrins: versatility, modulation, and signaling in cell Adhesion, 1992,Cell,69:11-25.
Lehmann, et al., A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins αvβ3, and αvβ6, 1994,Cancer Res.,54:2102-2107.
Matsuno, et al., Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation, 1994,Circulation,90(5):2203-2205.
Timar, et al., The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells, 1996,Eur. J. Cancer,32A(1):152-159.
Aimes, et al., Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation, 1994, Biochem. J., 300:729-736.
Friedlander, et al., Definition of two angiogenic pathways by distinct αv integrins, 1995,Science,270:1500-1502.
Pfaff, et al., Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins αIIbβ3, αvβ3 and α5β1 and in cell adhesion inhibition, 1994,Cell Adhes. Commun.,2(6):491-501.
Smith, et al., Interaction of integrins αvβ3 and glycoprotein IIb-IIIa with fibrinogen, 1990,J. Biol. Chem.,265:12267-12271.
Mueller, et al., Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells,Antibody, Immunoconjugates, and Radiopharmaceuticals,1991, 4(2):99-106.
Ossowski, et al., Experimental model for quantitative study of metastasis, 1980,Cancer Res.,40:2300-2309.
Drake, et al., A antagonist of integrin αvβ3 prevent maturation of blood vessels during embryonic neovascularization, 1995,J. Cell Sci.,108:2655-2661.
Cheresh, et al., “Recognition of Distinct Adhesive Sites on Fibrinogen by Related Integrins on Platelets and Endothelial Cells”,Cell 58:945-953 (1989).
D'Amato, et al., “Thalidomide is an Inhibitor of Angiogenesis”,Proc. Natl. Acad. Sci. USA 91:4082-4085 (1994).
Leibovich, et al., “Macrophage-induced Angiogenesis is Mediated by Tumour Necrosis Factor-α”,Nature 329:630-632 (1987).
Pfaff, et al., “Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by αIibβ3, and α5β1 Integrins”,J. of Biol. Chem. 269(32):20233-20238 (1994).
Yan, et al., “Human/Severe Combined Immunodeficient Mouse Chimeras: An Experimental in Vivo Model System to Study the Regulation of Human Endothelial Cell-Leukocyte Adhesion Molecules”,J. Clin. Invest, 91:986-996 (1993).
Gurrath, et al., “Conformation/Activity Studies of Rationally Designed Potent Anti-Adhesive RGD Peptides”,Eur. J. Biochem 210:911-921 (1992).
Leven, et al., “Extracellular Matrix Stimulation of Guinea Pig Megakaryocyte Proplatelet Formation in vitro is Mediated Through the Vitronectin Receptor”,Exp. Hematol. 20:1316-1322 (1992).
Lafrenie, et al., “Up-regulated Biosynthesis and Expression of Endothelial Cell Vitronectin Receptor Enhances Cancer Cell Adhesion”,Canc. Res. 52:2202-2208 (1992).
Klein, et al., “Basic Fibroblast Growth Factor Modulates Integrin Expression in Microvasular Endothelial Cells”,Mol. Bio. of the Cell 4:973-982 (1993).
Swerlick, et al., “Expression and Modulation of the Vitronectin Receptor on Human Dermal Microvascular Endothelial Cells”,J. of Inves. Derm. 99(6): 715-722 (1992).
Brooks, et al., “Subtractive Immunization Yields Monoclonal Antibodies that Specifically Inhibit Metastasis”,J. of Cell Biol. 122(6): 1351-1359 (1993).
Nip, et al., “Human Melanoma Cells Derived from Lymphatic Metastases Use Integrin αvβ3to Adhere to Lymph Node Vitronectin”,J. Clin. Invest. 90:1406-1413 (1992).
Jackson, et al., “Isolation and Propagation of Endothelial Cells Derived from Rheumatoid Synovial Microvasculature”,Ann. of the Rheu. Dis. 48:733-736 (1989).
Waldman, Thomas A., “Monoclonal Antibodies in Diagnosis and Therapy”,Science 252:1657-1662 (1991).
Brooks, et al., “Requirement of Vascular Integrin αvβ3for Angigenesis”,Science 264:569-570 (1994).
Chuntharapai, et al., “Blocking Monoclonal Antibodies to αVβ3 Integrin: A Unique Epitope of αVβ3 Integrin is Present on Human Osteoclasts”,Exper. Cell Res. 205:345-352 (1993).
Osband, et al., “Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy”,Imm. Today 11(6): 193-195 (1990
Brooks Peter
Cheresh David A.
Fitting Thomas
Gambel Phillip
Holmes Emily
The Scripps Research Institute
LandOfFree
Inhibition of angiogenesis in disease states with an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of angiogenesis in disease states with an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of angiogenesis in disease states with an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3380715